FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1985158166> ?p ?o ?g. }

• W1985158166 endingPage "e1493" @default.
• W1985158166 startingPage "e1493" @default.
• W1985158166 abstract "Previous research indicates that a combination vaccine targeting different stages of the malaria life cycle is likely to provide the most effective malaria vaccine. This trial was the first to combine two existing vaccination strategies to produce a vaccine that induces immune responses to both the pre-erythrocytic and blood stages of the P. falciparum life cycle.This was a Phase I/IIa study of a new combination malaria vaccine FFM ME-TRAP+PEV3A. PEV3A includes peptides from both the pre-erythrocytic circumsporozoite protein and the blood-stage antigen AMA-1. This study was conducted at the Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Oxford, UK. The participants were healthy, malaria naïve volunteers, from Oxford. The interventions were vaccination with PEV3A alone, or PEV3A+FFM ME-TRAP. The main outcome measure was protection from malaria in a sporozoite challenge model. Other outcomes included measures of parasite specific immune responses induced by either vaccine; and safety, assessed by collection of adverse event data.We observed evidence of blood stage immunity in PEV3A vaccinated volunteers, but no volunteers were completely protected from malaria. PEV3A induced high antibody titres, and antibodies bound parasites in immunofluorescence assays. Moreover, we observed boosting of the vaccine-induced immune response by sporozoite challenge. Immune responses induced by FFM ME-TRAP were unexpectedly low. The vaccines were safe, with comparable side effect profiles to previous trials. Although there was no sterile protection two major observations support an effect of the vaccine-induced response on blood stage parasites: (i) Lower rates of parasite growth were observed in volunteers vaccinated with PEV3A compared to unvaccinated controls (p = 0.012), and this was reflected in the PCR results from PEV3A vaccinated volunteers. These showed early control of parasitaemia by some volunteers in this group. One volunteer, who received PEV3A alone, was diagnosed very late, on day 20 compared to an average of 11.8 days in unvaccinated controls. (ii). Morphologically abnormal parasites were present in the blood of all (n = 24) PEV3A vaccinated volunteers, and in only 2/6 controls (p = 0.001). We describe evidence of vaccine-induced blood stage efficacy for the first time in a sporozoite challenge study." @default.
• W1985158166 created "2016-06-24" @default.
• W1985158166 creator A5019942781 @default.
• W1985158166 creator A5026314935 @default.
• W1985158166 creator A5037138357 @default.
• W1985158166 creator A5040896653 @default.
• W1985158166 creator A5040981678 @default.
• W1985158166 creator A5044634375 @default.
• W1985158166 creator A5051277836 @default.
• W1985158166 creator A5051618862 @default.
• W1985158166 creator A5055645256 @default.
• W1985158166 creator A5057390212 @default.
• W1985158166 creator A5057807377 @default.
• W1985158166 creator A5069194740 @default.
• W1985158166 creator A5077458377 @default.
• W1985158166 creator A5078693210 @default.
• W1985158166 creator A5079914158 @default.
• W1985158166 creator A5081142951 @default.
• W1985158166 creator A5089382312 @default.
• W1985158166 creator A5091175877 @default.
• W1985158166 date "2008-01-30" @default.
• W1985158166 modified "2023-10-12" @default.
• W1985158166 title "Evidence of Blood Stage Efficacy with a Virosomal Malaria Vaccine in a Phase IIa Clinical Trial" @default.
• W1985158166 cites W1926917528 @default.
• W1985158166 cites W1978059116 @default.
• W1985158166 cites W2008629172 @default.
• W1985158166 cites W2013628180 @default.
• W1985158166 cites W2017715529 @default.
• W1985158166 cites W2021978202 @default.
• W1985158166 cites W2023871112 @default.
• W1985158166 cites W2039179861 @default.
• W1985158166 cites W2065617509 @default.
• W1985158166 cites W2067428749 @default.
• W1985158166 cites W2070345715 @default.
• W1985158166 cites W2085313180 @default.
• W1985158166 cites W2095135796 @default.
• W1985158166 cites W2100309118 @default.
• W1985158166 cites W2114643485 @default.
• W1985158166 cites W2120416061 @default.
• W1985158166 cites W2126082637 @default.
• W1985158166 cites W2126344726 @default.
• W1985158166 cites W2128284066 @default.
• W1985158166 cites W2129193946 @default.
• W1985158166 cites W2129304079 @default.
• W1985158166 cites W2145303222 @default.
• W1985158166 cites W2147862160 @default.
• W1985158166 cites W2151497677 @default.
• W1985158166 cites W2155144810 @default.
• W1985158166 cites W2155641739 @default.
• W1985158166 cites W2156022009 @default.
• W1985158166 cites W2160473798 @default.
• W1985158166 cites W2169945363 @default.
• W1985158166 cites W2239593703 @default.
• W1985158166 cites W2330060906 @default.
• W1985158166 cites W2340524139 @default.
• W1985158166 cites W2889310554 @default.
• W1985158166 doi "https://doi.org/10.1371/journal.pone.0001493" @default.
• W1985158166 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2204057" @default.
• W1985158166 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18231580" @default.
• W1985158166 hasPublicationYear "2008" @default.
• W1985158166 type Work @default.
• W1985158166 sameAs 1985158166 @default.
• W1985158166 citedByCount "103" @default.
• W1985158166 countsByYear W19851581662012 @default.
• W1985158166 countsByYear W19851581662013 @default.
• W1985158166 countsByYear W19851581662014 @default.
• W1985158166 countsByYear W19851581662015 @default.
• W1985158166 countsByYear W19851581662016 @default.
• W1985158166 countsByYear W19851581662017 @default.
• W1985158166 countsByYear W19851581662018 @default.
• W1985158166 countsByYear W19851581662019 @default.
• W1985158166 countsByYear W19851581662020 @default.
• W1985158166 countsByYear W19851581662021 @default.
• W1985158166 countsByYear W19851581662022 @default.
• W1985158166 countsByYear W19851581662023 @default.
• W1985158166 crossrefType "journal-article" @default.
• W1985158166 hasAuthorship W1985158166A5019942781 @default.
• W1985158166 hasAuthorship W1985158166A5026314935 @default.
• W1985158166 hasAuthorship W1985158166A5037138357 @default.
• W1985158166 hasAuthorship W1985158166A5040896653 @default.
• W1985158166 hasAuthorship W1985158166A5040981678 @default.
• W1985158166 hasAuthorship W1985158166A5044634375 @default.
• W1985158166 hasAuthorship W1985158166A5051277836 @default.
• W1985158166 hasAuthorship W1985158166A5051618862 @default.
• W1985158166 hasAuthorship W1985158166A5055645256 @default.
• W1985158166 hasAuthorship W1985158166A5057390212 @default.
• W1985158166 hasAuthorship W1985158166A5057807377 @default.
• W1985158166 hasAuthorship W1985158166A5069194740 @default.
• W1985158166 hasAuthorship W1985158166A5077458377 @default.
• W1985158166 hasAuthorship W1985158166A5078693210 @default.
• W1985158166 hasAuthorship W1985158166A5079914158 @default.
• W1985158166 hasAuthorship W1985158166A5081142951 @default.
• W1985158166 hasAuthorship W1985158166A5089382312 @default.
• W1985158166 hasAuthorship W1985158166A5091175877 @default.
• W1985158166 hasBestOaLocation W19851581661 @default.
• W1985158166 hasConcept C126322002 @default.
• W1985158166 hasConcept C159047783 @default.
• W1985158166 hasConcept C159654299 @default.

• next